David Lucchino has been a leader in the life science industry for more than two decades, as an executive, an entrepreneur, an investor and an advocate. He was recently named President and CEO of Brenig Therapeutics, a biotech company developing small molecule therapeutics for neurodegenerative diseases. Prior to Brenig, he was the President and CEO of Frequency Therapeutics, a company he co-founded in 2014 and took public in 2019. Frequency was as a regenerative medicine company, born out of the labs of the renown MIT Institute Professor Robert Langer, with programs for sensorineural hearing loss and remyelination in multiple sclerosis. In 2005, David co-founded Semprus BioSciences (also with Dr. Langer). There he guided its lead product, a device that reduces blood clotting on medical devices, to FDA approval and European CE-Marking. Semprus was subsequently sold to Teleflex (NYSE: TFX). Previously, David worked at the Boston-based venture capital firm Polaris Partners, where he focused on healthcare investing and portfolio company board recruitment. He began his career as a co-founder and managing director at LaunchCyte, a venture incubator based out of the University of Pittsburgh Medical Center that helped form several biotech startups. David is the past Chairman of MassBio and remains a board member. He was appointed by former Governor Charlie Baker to the Massachusetts STEM Advisory Council and is a member of the College of Fellows for the American Institute of Medical and Biological Engineering. David also serves on the boards of the Multiple Myeloma Research Foundation and Siloam Vision David earned a B.A. from Denison University, an M.S. from the Newhouse School of Public Communications at Syracuse University, and an M.B.A. from the MIT Sloan School of Management as an Alfred P. Sloan Fellow.